HLS Therapeutics Inc. (FRA:74D)

Market Cap	92.68M
Revenue (ttm)	47.60M
Net Income (ttm)	-12.03M
Shares Out	n/a
EPS (ttm)	-0.38
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	2.780
Previous Close	2.740
Day's Range	2.780 - 2.780
52-Week Range	2.280 - 3.420
Beta	n/a
RSI	43.54
Earnings Date	Mar 12, 2026

About HLS Therapeutics

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders, central nervous system, and cardiovascular disease in Canada, the United States, and internationally. The company’s lead products include Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care de...

• Industry: Pharmaceutical Preparations
• CEO: Craig Millian
• Employees: 92
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 74D

Financial Performance

In 2024, HLS Therapeutics's revenue was $56.62 million, a decrease of -10.23% compared to the previous year's $63.07 million. Losses were -$19.66 million, -28.61% less than in 2023.

Financial numbers in USD